|
Post by dreamboatcruise on Dec 2, 2014 15:07:02 GMT -5
Is anyone using the web link on Mannkind website? A title slide came up but nothing else and I hear no audio.
|
|
|
Post by brentie on Dec 2, 2014 15:14:46 GMT -5
Try signing in again.I'm listening but I had a hard time getting it too. Matt and Hakan are answering questions, so far it's all about Afrezza.
|
|
|
Post by bradleysbest on Dec 2, 2014 15:21:30 GMT -5
Technosphere opportunities to be revealed after Afrezza launch! Matt admitted they have not been forthcoming with Technosphere .....
|
|
|
Post by dreamboatcruise on Dec 2, 2014 15:21:43 GMT -5
Thanks for log in advice Brentie... switched to a different browser and got on. Did I miss them announcing the projected revenue for 2015? (OMG... I crack myself up at times ) [message edited since I accidentally made it reply to wrong person]
|
|
|
Post by kc on Dec 2, 2014 15:22:47 GMT -5
Disclose in a bulk fashion like a sale of the company in February 2015 to MDT.
|
|
|
Post by bradleysbest on Dec 2, 2014 15:24:38 GMT -5
Something is a brewing......
|
|
|
Post by dreamboatcruise on Dec 2, 2014 15:26:45 GMT -5
Like the correction when "early years" was misspoken in references to losses and corrected that they hoped profitability would be quicker than that.
|
|
|
Post by dreamboatcruise on Dec 2, 2014 15:28:38 GMT -5
Potential "agreements" in place with regard to new technosphere products and announced after February board meeting.
|
|
|
Post by dreamboatcruise on Dec 2, 2014 15:34:16 GMT -5
Disclose in a bulk fashion like a sale of the company in February 2015 to MDT. Is that why Matt was wearing a shirt with the Medtronic logo?
|
|
|
Post by kc on Dec 2, 2014 15:47:51 GMT -5
Next up on Wed Morning at 9:00 am ET. is Amphstar. I wonder if any questions about the MannKind insulin buy will be asked. Dec 3, 2014
9:00 AM ET Piper Jaffray 26th Annual Healthcare Conference www.media-server.com/m/p/2gfypwe8perhaps worth listening to it. (this information below was from the Amphstar presentation they gave back in October.)
■ Recombinant Human Insulin (RHI) − Signed supply agreement with MannKind to supply RHI for AFREZZA® − Agreement specifies minimum annual sales of 24 million euros annually for 5 years from 2015 - 2019 − Further amounts may be purchased
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 2, 2014 15:59:25 GMT -5
Disclose in a bulk fashion like a sale of the company in February 2015 to MDT. Is that why Matt was wearing a shirt with the Medtronic logo? Dream, you are one of the few here with the sense of humor needed to appreciate these clowns known as management. They are at least as good as a Marx Brothers movie.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 2, 2014 17:59:27 GMT -5
With all due respect to the passive aggressiveness some exhibit towards management here, there were a few things in the conference that are extremely important. First, they clarified the cost structure and gave some important examples how and what triggers MNKD paying for sales force costs, it's linked to sales success not sales size. That's big. As is that multiple milestones are about to be announced, which we've all been able to deduce are more than likely commissioning and startup of approved lines 2/3.
They gave some not so discreet hints at technosphere timelines, and even talked about ramping up spend towards things "not afrezza related".
I hope there's a transcript put together because I missed a few pieces of the telecom that I want to go back over.
All in all, mock management that they arent exactly awesome motivational speakers but things are headed in the right direction
|
|
|
Post by dreamboatcruise on Dec 2, 2014 18:47:07 GMT -5
With all due respect to the passive aggressiveness some exhibit towards management here, there were a few things in the conference that are extremely important. First, they clarified the cost structure and gave some important examples how and what triggers MNKD paying for sales force costs, it's linked to sales success not sales size. That's big. As is that multiple milestones are about to be announced, which we've all been able to deduce are more than likely commissioning and startup of approved lines 2/3. They gave some not so discreet hints at technosphere timelines, and even talked about ramping up spend towards things "not afrezza related". I hope there's a transcript put together because I missed a few pieces of the telecom that I want to go back over. All in all, mock management that they arent exactly awesome motivational speakers but things are headed in the right direction Thanks for posting those comments. I missed most of it because of "technical difficulties". I certainly look forward to reading the comment about the sales force costs. That was a big question in my mind and the answer you give is great news. I do believe in the Mannkind team's ability to craft a good agreement (if not put on a good Vegas style floor show), and this would be another example of that. I've always stated that despite what might have been an initial bit of disappointment at 35%, I think the overall deal including the larger split to SNY was a way of creating a win-win that incentivizes SNY to push Afrezza as hard as Lantus. This sales cost split is another example where SNY, in light of potentially falling Lantus revenue, will be rewarded on the bottom line by producing Afrezza sales in order to shift sales costs into the Afrezza column. .. but they only get to do it by producing results for Mannkind. BTW... hopefully I'm not one of the one's you consider passive aggressive... lizards are known for being a bit flippant, so any of my occasional griping or poking fun at management is in the overall context of my gratitude that they have seen this through, not only to my financial benefit, but also the huge benefit to patients.
|
|
|
Post by dreamboatcruise on Dec 2, 2014 19:59:20 GMT -5
I just managed to listen to the entire thing. I think another important statement made by Matt is that the $175M loan to cover their share of the losses before profits start was padded and that they anticipate their share of the losses should be significantly less... i.e. we're not likely to get close to where shorts can claim more dilutive equity issuing will be done.
The weakest part I thought was when basically confronted with questioning that implied... "you've just stated you view your biggest opportunity as the needle phobic but given that the stick for a blood sugar meter is now as painful or worse than the prandial pens, how is that a strong selling point?" [my paraphrasing into a much more direct, confrontational question than the way it was really asked] The response was basically... "well, Sanofi would be the ones to know that." I think that could have been answered more positively given feedback they've received from patients... perhaps also talking about social aspects of injecting in public and long term physical detrimental effects of injections beyond the simple feel of an individual stick.
|
|
|
Post by jpg on Dec 2, 2014 20:16:18 GMT -5
I just managed to listen to the entire thing. I think another important statement made by Matt is that the $175M loan to cover their share of the losses before profits start was padded and that they anticipate their share of the losses should be significantly less... i.e. we're not likely to get close to where shorts can claim more dilutive equity issuing will be done. The weakest part I thought was when basically confronted with questioning that implied... "you've just stated you view your biggest opportunity as the needle phobic but given that the stick for a blood sugar meter is now as painful or worse than the prandial pens, how is that a strong selling point?" [my paraphrasing into a much more direct, confrontational question than the way it was really asked] The response was basically... "well, Sanofi would be the ones to know that." I think that could have been answered more positively given feedback they've received from patients... perhaps also talking about social aspects of injecting in public and long term physical detrimental effects of injections beyond the simple feel of an individual stick. Finger sticks hurt a lot. Other ways (areas) of sampling much less. When doing a blood sugar level you are sampling and not injecting. Big difference when doing it or thinking of doing it. What many who focus only on the pain part of the equation fail to understand is that 'pain of injecting' isn't all about acute very transitory and temporary pain. The image of injecting, the perception of injecting, the perception of others looking at you injecting (bathroom in a public place etc) is all part of the experience. The notion that injecting means you are sicker then pills or inhalers (although not necessarily true) is also very common. This may all sound esoteric but not when you are the one doing the injections on yourself. Those that are used to injection also often minimize the pain of injecting because they have basically no choice... JPG
|
|